JP2014523421A - 抗ｄｌｌ４抗体を使用して腫瘍治療における放射線に対する反応を増大させる方法 - Google Patents

抗ｄｌｌ４抗体を使用して腫瘍治療における放射線に対する反応を増大させる方法 Download PDF

Info

Publication number
JP2014523421A
JP2014523421A JP2014516039A JP2014516039A JP2014523421A JP 2014523421 A JP2014523421 A JP 2014523421A JP 2014516039 A JP2014516039 A JP 2014516039A JP 2014516039 A JP2014516039 A JP 2014516039A JP 2014523421 A JP2014523421 A JP 2014523421A
Authority
JP
Japan
Prior art keywords
dll4
cancer
tumor
antibody
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014516039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523421A5 (enExample
Inventor
ハリス，エイドリアン，エル．
ケイ． リウ，スタンレイ
マシェル，ルース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2014523421A publication Critical patent/JP2014523421A/ja
Publication of JP2014523421A5 publication Critical patent/JP2014523421A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
JP2014516039A 2011-06-17 2012-06-15 抗ｄｌｌ４抗体を使用して腫瘍治療における放射線に対する反応を増大させる方法 Ceased JP2014523421A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498200P 2011-06-17 2011-06-17
US61/498,200 2011-06-17
PCT/US2012/042695 WO2012174394A1 (en) 2011-06-17 2012-06-15 Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies

Publications (2)

Publication Number Publication Date
JP2014523421A true JP2014523421A (ja) 2014-09-11
JP2014523421A5 JP2014523421A5 (enExample) 2015-08-06

Family

ID=46397640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516039A Ceased JP2014523421A (ja) 2011-06-17 2012-06-15 抗ｄｌｌ４抗体を使用して腫瘍治療における放射線に対する反応を増大させる方法

Country Status (6)

Country Link
US (1) US8685401B2 (enExample)
EP (1) EP2721070A1 (enExample)
JP (1) JP2014523421A (enExample)
AU (1) AU2012271450A1 (enExample)
CA (1) CA2838973A1 (enExample)
WO (1) WO2012174394A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020523412A (ja) * 2017-06-12 2020-08-06 アジオス ファーマシューティカルズ， インコーポレイテッド 併用療法を用いて脳腫瘍を処置する方法
JP2020523344A (ja) * 2017-06-12 2020-08-06 アジオス ファーマシューティカルズ， インコーポレイテッド 併用療法を用いて脳腫瘍を処置する方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2488204T3 (pl) 2009-10-16 2016-10-31 Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych
DK3485903T5 (da) 2011-09-23 2024-09-02 Mereo Biopharma 5 Inc Vegf/dll4-bindende midler og anvendelser deraf
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504755A (ja) * 2006-09-29 2010-02-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US20100196385A1 (en) * 2008-09-19 2010-08-05 Medlmmune Llc Targeted binding agents directed to dll4 and uses thereof 524

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20110059114A1 (en) 2009-08-05 2011-03-10 Duke University Compositions and Methods for the Treatment of Radioresistant Glioma Stem Cells
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010504755A (ja) * 2006-09-29 2010-02-18 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
US20100196385A1 (en) * 2008-09-19 2010-08-05 Medlmmune Llc Targeted binding agents directed to dll4 and uses thereof 524

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5014007795; Ｓ　Ｋ　ＬＩＵ: 'ＤＥＬＴＡ-ＬＩＫＥ　ＬＩＧＡＮＤ　４-ＮＯＴＣＨ　ＢＬＯＣＫＡＤＥ　ＡＮＤ　ＴＵＭＯＲ　ＲＡＤＩＡＴＩＯＮ　ＲＥＳＰＯＮＳＥ' ＪＮＣＩ　ＪＯＵＲＮＡＬ　ＯＦ　ＴＨＥ　ＮＡＴＩＯＮＡＬ　ＣＡＮＣＥＲ　ＩＮＳＴＩＴＵＴＥ Ｖ１０３　Ｎ２３, 20111207, Ｐ１７７８-１７９８ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020523412A (ja) * 2017-06-12 2020-08-06 アジオス ファーマシューティカルズ， インコーポレイテッド 併用療法を用いて脳腫瘍を処置する方法
JP2020523344A (ja) * 2017-06-12 2020-08-06 アジオス ファーマシューティカルズ， インコーポレイテッド 併用療法を用いて脳腫瘍を処置する方法
US11458127B2 (en) 2017-06-12 2022-10-04 Agios Pharmaceuticals, Inc. Methods of treating brain tumors using combination therapy
JP2023025277A (ja) * 2017-06-12 2023-02-21 アジオス ファーマシューティカルズ， インコーポレイテッド 併用療法を用いて脳腫瘍を処置する方法
JP7263665B2 (ja) 2017-06-12 2023-04-25 レ ラボラトワール セルヴィエ 併用療法を用いて脳腫瘍を処置する方法
JP7263669B2 (ja) 2017-06-12 2023-04-25 レ ラボラトワール セルヴィエ 併用療法を用いて脳腫瘍を処置する方法

Also Published As

Publication number Publication date
AU2012271450A1 (en) 2014-01-16
CA2838973A1 (en) 2012-12-20
US8685401B2 (en) 2014-04-01
US20130006034A1 (en) 2013-01-03
WO2012174394A1 (en) 2012-12-20
EP2721070A1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
KR102628557B1 (ko) 폐암의 치료를 위한 항-pd-1 항체
TWI780994B (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
MD3455259T2 (ro) Combinație de anticorpi anti-PD-1 și radiație pentru tratarea cancerului
JP2024508894A (ja) Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
CN116327924A (zh) 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
TW201922793A (zh) Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途
US20220265844A1 (en) Dosing regimens for anti-tf-antibody drug-conjugates
JP2021522298A (ja) 癌治療のためのＰＤ−１／ＰＤ−Ｌ１、ＴＧＦβおよびＤＮＡ−ＰＫの同時阻害
CN110494161A (zh) 用于治疗癌症的抗pd-l1抗体和dna-pk抑制剂的组合
JP7460608B2 (ja) 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
US11572405B2 (en) Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
JP2023502585A (ja) 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害
US8685401B2 (en) Methods of enhancing the response to radiation in tumor therapy using anti-DLL4 antibodies
US20240327519A1 (en) Methods and compositions for treating cancer
WO2025103441A1 (zh) 联合抗her2抗体和化疗剂治疗胃癌的方法及用途
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
JP7240512B2 (ja) Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法
TW202430209A (zh) 單獨使用雙特異性EGFR x CD28抗體或其與抗PD-1抗體組合使用治療癌症之方法
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
CN121152804A (zh) 用抗mica/b抗体治疗癌症的方法
TW202508632A (zh) 使用抗ｐｄ－１及化學療法治療肺癌
TW202502382A (zh) 治療組合及其用途和治療方法
TW202502813A (zh) 包含偶聯物的藥物組合的治療方法和用途
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160602

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160927

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20170131